The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I study of novel dual Bcl-2/Bcl-xL inhibitor APG-1252 in patients with advanced small cell lung cancer (SCLC) or other solid tumor.
 
Nehal J. Lakhani
Research Funding - Abbvie (Inst); Alexion Pharmaceuticals (Inst); Alexo Therapeutics (Inst); Amgen (Inst); ArQule (Inst); Asana Biosciences (Inst); Ascentage Pharma (Inst); BeiGene (Inst); Cerulean Pharma (Inst); Constellation Pharmaceuticals (Inst); Daiichi Sankyo (Inst); Dicerna (Inst); Forty Seven (Inst); Loxo (Inst); Macrogenics (Inst); Merck (Inst); Pfizer (Inst); Regeneron (Inst); Symphony Evolution (Inst); TaiRx, Inc. (Inst)
 
Drew W. Rasco
Employment - START
Consulting or Advisory Role - Boehringer Ingelheim; Lilly; TaiRx, Inc.
Research Funding - Abbvie (Inst); Aeglea Biotherapeutics (Inst); Apexian Pharmaceuticals (Inst); Asana Biosciences (Inst); Ascentage Pharma (Inst); Birdie (Inst); Celgene (Inst); Constellation Pharmaceuticals (Inst); Eisai (Inst); Five Prime Therapeutics (Inst); Macrogenics (Inst); Merck (Inst); Millennium (Inst); Pharmacyclics (Inst); Rexahn Pharmaceuticals (Inst); Santa Maria Biotherapeutics (Inst); Syndax (Inst)
Travel, Accommodations, Expenses - Asana Biosciences
 
Anthony W. Tolcher
Employment - New Experimental; START
Leadership - Symphony Evolution
Consulting or Advisory Role - AbbVie (Inst); Ascentage Pharma (Inst); Astex Pharmaceuticals (Inst); Bicycle Therapeutics (Inst); BioInvent (Inst); Boehringer Ingelheim (Inst); Elekta (Inst); EMD Serono (Inst); Formation Biologics (Inst); Genmab (Inst); Idea Pharma (Inst); Ignyta (Inst); Johnson & Johnson (Inst); MEDIAN Technologies (Inst); Merus (Inst); Nanobiotix (Inst); New B Innovation (Inst); OncoMed (Inst); Pierre Fabre (Inst); Rigontec (Inst); Symphony Evolution (Inst); Zymeworks (Inst)
Research Funding - AbbVie (Inst); Alexion Pharmaceuticals (Inst); Asana Biosciences (Inst); Astex Pharmaceuticals (Inst); Bayer (Inst); EMD Serono (Inst); Gilead Sciences (Inst); Infinity Pharmaceuticals (Inst); Jounce Therapeutics (Inst); Macrogenics (Inst); Otsuka (Inst); Pfizer (Inst); Plexxikon (Inst); Syndax (Inst); Syros Pharmaceuticals (Inst); TaiRx, Inc. (Inst)
 
Yingjie Huang
Employment - Ascentage Pharma
 
Jiao Ji
Employment - Ascentage Pharma
 
Hengbang Wang
Employment - Ascentage Pharma
 
Qi Dong
Employment - Ascentage Pharma
 
Lichuang Men
Employment - Ascentage Pharma
 
Timothy J. O'Rourke
Research Funding - Asana Biosciences (Inst)
 
Sreenivasa R Chandana
Honoraria - HERON
Consulting or Advisory Role - HERON
Research Funding - Abbvie (Inst); Alexion Pharmaceuticals (Inst); Alexion Pharmaceuticals (Inst); Alexo Therapeutics (Inst); ArQule (Inst); Asana Biosciences (Inst); Ascentage Pharma (Inst); BeiGene (Inst); Cerulean Pharma (Inst); Constellation Pharmaceuticals (Inst); Daiichi Sankyo (Inst); Dicerna (Inst); Formation Biologics (Inst); Forty Seven (Inst); Livzon (Inst); Loxo (Inst); Macrogenics (Inst); Merck (Inst); Pfizer (Inst); Regeneron (Inst); Symphony Evolution (Inst); TaiRx, Inc. (Inst)
 
Alex Amaya
No Relationships to Disclose
 
Yvette Cole
No Relationships to Disclose
 
Brianne Kaiser
No Relationships to Disclose
 
Theresa A. Mays
No Relationships to Disclose
 
Amita Patnaik
Consulting or Advisory Role - Bayer
Research Funding - Abbvie; Aeglea Biotherapeutics; Alexion Pharmaceuticals; Amgen; Asana Biosciences; Ascentage Pharma Group; Astex Pharmaceuticals; AVEO (Inst); Bayer; Bayer (Inst); Calithera Biosciences; Celgene (Inst); Cerulean Pharma (Inst); Corvus Pharmaceuticals (Inst); Daiichi Sankyo (Inst); Eisai (Inst); EMD Serono (Inst); Endocyte (Inst); Five Prime Therapeutics (Inst); Formation Biologics (Inst); Forty Seven; Gilead Sciences (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Jiangsu Hengrui Medicine; Jiangsu Hengrui Medicine (Inst); Lilly (Inst); Macrogenics (Inst); Merck (Inst); Merck Sharp & Dohme; Novartis; OncoMed; Pfizer (Inst); Plexxikon; Plexxikon (Inst); Regeneron (Inst); Symphony Evolution (Inst); TaiRx, Inc. (Inst); Tesaro (Inst); Tesaro (Inst); Teva (Inst); Upsher-Smith; Zymeworks (Inst)
 
Kyriakos P. Papadopoulos
Research Funding - 3D Medicines (Inst); Abbvie (Inst); ADC Therapeutics (Inst); Amgen (Inst); ARMO BioSciences (Inst); ArQule (Inst); Calithera Biosciences (Inst); Curegenix (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Formation Biologics (Inst); GlaxoSmithKline (Inst); Incyte (Inst); MedImmune (Inst); Merck (Inst); Peloton Therapeutics (Inst); Regeneron (Inst); Sanofi (Inst)
 
Dajun Yang
Employment - Ascentage Pharma
 
Yifan Zhai
Employment - Ascentage Pharma